Sinha Rohit, Lockman Khalida A, Homer Natalie Z M, Bower Edward, Brinkman Paul, Knobel Hugo H, Fallowfield Jonathan A, Jaap Alan J, Hayes Peter C, Plevris John N
Hepatology Laboratory and Centre for Liver and Digestive Disorders, Royal Infirmary of Edinburgh and The University of Edinburgh, Edinburgh, UK.
Edinburgh Acute & General Medicine, Royal Infirmary of Edinburgh and The University of Edinburgh, Edinburgh, UK.
JHEP Rep. 2020 Jun 15;2(5):100137. doi: 10.1016/j.jhepr.2020.100137. eCollection 2020 Oct.
BACKGROUND & AIMS: Analysis of volatile organic compounds (VOCs) in exhaled breath, 'volatomics', provides opportunities for non-invasive biomarker discovery and novel mechanistic insights into a variety of diseases. The purpose of this pilot study was to compare breath VOCs in an initial cohort of patients with non-alcoholic fatty liver disease (NAFLD) and healthy controls.
Breath samples were collected from 15 participants with Child-Pugh class A NAFLD cirrhosis, 14 with non-cirrhotic NAFLD, and 14 healthy volunteers. Exhaled breath samples were collected using an established methodology and VOC profiles were analysed by gas chromatography-mass spectrometry. The levels of 19 VOCs previously associated with cirrhosis were assessed. Peaks of the VOCs were confirmed and integrated using Xcalibur® software, normalised to an internal standard. Receiver-operating characteristic (ROC) curves were used to determine the diagnostic accuracy of the candidate VOCs.
Terpinene, dimethyl sulfide, and D-limonene provided the highest predictive accuracy to discriminate between study groups. Combining dimethyl sulfide with D-limonene led to even better discrimination of patients with NAFLD cirrhosis from healthy volunteers (AUROC 0.98; 95% CI 0.93-1.00; <0.001) and patients with NAFLD cirrhosis from those with non-cirrhotic NAFLD (AUROC 0.91; 95% CI 0.82-1.00; <0.001). Breath terpinene concentrations discriminated between patients with non-cirrhotic NAFLD and healthy volunteers (AUROC 0.84; 95% CI 0.68-0.99; = 0.002).
Breath terpinene, dimethyl sulfide, and D-limonene are potentially useful volatomic markers for stratifying NAFLD; in addition, a 2-stage approach enables the differentiation of patients with cirrhosis from those without. However, these observations require validation in a larger NAFLD population. (ClinicalTrials.gov Identifier: NCT02950610).
Breath malodour has been associated with a failing liver since the ancient Greeks. Analytical chemistry has provided us an insight into ubiquitous volatile organic compounds associated with liver (and other) diseases. This has vastly improved our understanding of the mechanistic processes of liver damage. Our study aims to identify volatile organic compounds which are specific to non-alcoholic fatty liver disease and that can be exploited for rapid diagnostics.
对呼出气体中的挥发性有机化合物(VOCs)进行分析,即“挥发组学”,为非侵入性生物标志物的发现以及对多种疾病的新机制洞察提供了机会。这项初步研究的目的是比较非酒精性脂肪性肝病(NAFLD)患者初始队列与健康对照者的呼出VOCs。
从15例Child-Pugh A级NAFLD肝硬化患者、14例非肝硬化NAFLD患者和14名健康志愿者中收集呼吸样本。使用既定方法收集呼出气体样本,并通过气相色谱-质谱法分析VOC谱。评估了先前与肝硬化相关的19种VOCs的水平。使用Xcalibur®软件确认并整合VOCs的峰,以内标进行归一化。采用受试者操作特征(ROC)曲线来确定候选VOCs的诊断准确性。
萜品烯、二甲基硫醚和D-柠檬烯在区分研究组方面具有最高的预测准确性。将二甲基硫醚与D-柠檬烯结合使用,能更好地区分NAFLD肝硬化患者与健康志愿者(曲线下面积[AUC]为0.98;95%置信区间[CI]为0.93 - 1.00;P<0.001)以及NAFLD肝硬化患者与非肝硬化NAFLD患者(AUC为0.91;95%CI为0.82 - 1.00;P<0.001)。呼出萜品烯浓度可区分非肝硬化NAFLD患者与健康志愿者(AUC为0.84;95%CI为0.68 - 0.99;P = 0.002)。
呼出萜品烯、二甲基硫醚和D-柠檬烯可能是用于对NAFLD进行分层的有用挥发组学标志物;此外,两阶段方法能够区分肝硬化患者与非肝硬化患者。然而,这些观察结果需要在更大的NAFLD人群中进行验证。(ClinicalTrials.gov标识符:NCT02950610)
自希腊人时代起,口臭就与肝脏功能衰竭有关。分析化学使我们能够深入了解与肝脏(及其他)疾病相关的普遍存在的挥发性有机化合物。这极大地增进了我们对肝损伤机制过程的理解。我们的研究旨在识别非酒精性脂肪性肝病特有的挥发性有机化合物,并将其用于快速诊断。